ArticleEuropean radiology2026
Diagnostic performance of dual-layer spectral detector CT in differentiating middle ear cholesteatoma from chronic suppurative otitis media.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Precision imaging biomarkers for gout: artifact-specific spectral CT parameters for personalized differentiation of tophi in a prospective study.Therapeutic advances in musculoskeletal disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo investigate the diagnostic performance of dual-layer spectral detector CT (DLCT) in differentiating middle ear cholesteatoma and chronic suppurative otitis media (CSOM). MATERIALS AND
methodsThis prospective, institutional review board-approved study consecutively enrolled patients with suspected middle ear cholesteatoma or CSOM from January to July 2024. All participants underwent DLCT scanning before surgery. Clinical average hearing threshold (AHT) was collected. Four blinded readers, with 2, 3, 11, and 13 years of experience, independently provided diagnoses, based on high-resolution CT (HRCT) or HRCT combined spectral images (integrated mode). Virtual mono-energetic images (VMIs) at 40 keV, spectral attenuation slope (λHU), and effective atomic number (Zeff) were measured. Intraoperative or pathological findings served as reference standards. Receiver operating characteristic (ROC) curve analysis was used.
resultsSixty-six participants (median age, 47.0 [33.0-55.0] years; 23 men, 33 with cholesteatoma) were included. The sensitivity of the integrated mode was 87.9%, significantly higher than HRCT alone (68.2%; p < 0.001), while specificities were 73.5% and 79.5% (p = 0.169), respectively. Diagnostic confidence scores of the integrated mode were significantly higher (p < 0.001). The Zeff, λHU, and VMI 40 keV of cholesteatoma were significantly lower (p < 0.001) than those of CSOM. AUCs of combined spectral model, integrated model and integrated model + AHT were 0.820 (95% CI: 0.744-0.882, p = 0.01), 0.817 (95% CI: 0.744-0.891, p = 0.017),0.853 (95% CI: 0.789-0.917, p = 0.001), respectively, all significantly higher than that of conventional HRCT (AUC = 0.741; 95% CI: 0.657-0.813).
conclusionHRCT combined with spectral images enhances the sensitivity of cholesteatoma diagnosis, and DLCT multi-parameters can quantitatively distinguish cholesteatoma from CSOM. KEY POINTS: Question HRCT is limited in differentiating middle ear cholesteatoma and CSOM. Findings Integrating HRCT and spectral images in DLCT increases the diagnostic sensitivity for cholesteatoma. Clinical relevance DLCT can provide valuable multi-parametric images. Its combination with HRCT significantly improves the diagnostic performance of middle ear cholesteatoma and CSOM, which may help clinicians make reasonable treatment plans.
Indexed as
Identifiers
40684067What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.